Sun Pharmaceutical Industries Ltd.
Sun House, Plot No. 201 B/1,
Western Express Highway,
Goregaon (East), Mumbai – 400063 India
Tel. : (91-22) 43244324 / 1234
Fax.: (91-22) 43244343
CIN: L24230GJ1993PLC019050, www.sunpharma.com

12 June 2018.

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Sub: Sun Pharma receives EIR for Halol facility

This is with reference to our letter dated June 08, 2018 to the stock exchanges providing our clarification on the US FDA inspection at the Company's Halol facility wherein interalia we had indicated that once we receive the Establishment Inspection Report (EIR), we would immediately inform the exchanges.

We are now pleased to inform you that we have received EIR in respect of which we are issuing the enclosed Press Release after sending this letter to you.

This is for your information and necessary dissemination.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Ltd

(Ashok I. Bhuta)

Compliance Officer

Encl: As above.

Sun Pharmaceutical Industries Ltd.
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com

FOR IMMEDIATE RELEASE

Sun Pharma receives EIR for Halol facility

Mumbai, India, June 12, 2018 - Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced that it has received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its Halol facility (Gujarat, India) during the period February 12-23, 2018. The agency concluded that the inspection is now closed and the issues contained in the Warning Letter issued in December 2015 have been addressed.

Commenting on the development, Dilip Shanghvi, Managing Director, Sun Pharma said, "This is an important development for Sun Pharma. We remain committed to following the highest levels of quality and 24x7 cGMP compliance at all our manufacturing facilities globally."

Disclaimer:
Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.

About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050):

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 41 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. In India, the company enjoys leadership across 13 different classes of doctors with 32 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 3 global markets. Its API business footprint is strengthened through 14 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of approximately 8% of annual revenues. For further information please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live

Contacts: Sun Pharma

Investors:

Nimish Desai	
Tel	+91 22 4324 4324, Xtn 2778
Tel Direct	+91 22 4324 2778
Mobile	+91-98203 30182
E mail	nimish.desai@sunpharma.com

Media:

Gaurav Chugh	
Tel	+91 22 4324 4324, Xtn 5373
Tel Direct	+91 22 4324 5373
Mobile	+91 98104 71414
E mail	gaurav.chugh@sunpharma.com